Literature DB >> 14769678

Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy.

Stephen D Wiviott1, Christopher P Cannon, David A Morrow, Sabina A Murphy, C Michael Gibson, Carolyn H McCabe, Marc S Sabatine, Nader Rifai, Robert P Giugliano, Peter M DiBattiste, Laura A Demopoulos, Elliott M Antman, Eugene Braunwald.   

Abstract

BACKGROUND: Diagnosis of coronary artery disease in women is more difficult because of lower specificity of symptoms and diagnostic accuracy of noninvasive testing. We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI). METHODS AND
RESULTS: In the TACTICS-TIMI 18, OPUS-TIMI 16, and TIMI 11 studies, baseline samples were analyzed in the Thrombolysis In Myocardial Infarction (TIMI) biomarker core laboratory. We examined the relationship between gender and elevated biomarkers. Of 1865 patients from TACTICS-TIMI 18, 34% were women. Fewer women had elevated creatine kinase-MB or troponins, whereas more had elevated high-sensitivity C-reactive protein or brain natriuretic peptide. Presence of ST-segment deviation and TIMI risk scores were not significantly different. This pattern was confirmed in TIMI 11 and OPUS-TIMI 16. The prognostic value of the markers in TACTICS-TIMI 18 was similar in women and men. When a multimarker approach was examined, a greater proportion of high-risk women were identified. Marker-positive patients of both genders had improved outcome with an invasive strategy; however, marker-negative women appeared to have improved outcomes with a conservative strategy.
CONCLUSIONS: In patients with UA/NSTEMI, there was a different pattern of presenting biomarkers. Men were more likely to have elevated creatine kinase-MB and troponins, whereas women were more likely to have elevated C-reactive protein and brain natriuretic peptide. This suggests that a multimarker approach may aid the initial risk assessment of UA/NSTEMI, especially in women. Further research is necessary to elucidate whether gender-related pathophysiological differences exist in presentation with acute coronary syndromes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769678     DOI: 10.1161/01.CIR.0000109491.66226.26

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  31 in total

1.  Proceedings from the scientific symposium: Sex differences in cardiovascular disease and implications for therapies.

Authors:  C Noel Bairey Merz; Saralyn Mark; Barbara D Boyan; Alice K Jacobs; Prediman K Shah; Leslee J Shaw; Doris Taylor; Eduardo Marbán
Journal:  J Womens Health (Larchmt)       Date:  2010-06       Impact factor: 2.681

2.  Sex, Myocardial Infarction, and the Failure of Risk Scores in Women.

Authors:  Shilpa Agrawal; Jennifer Van Eyk; Kimia Sobhani; Janet Wei; C Noel Bairey Merz
Journal:  J Womens Health (Larchmt)       Date:  2015-08-19       Impact factor: 2.681

Review 3.  Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes.

Authors:  Ankie Amos; L Kristin Newby
Journal:  Curr Cardiol Rep       Date:  2005-07       Impact factor: 2.931

4.  Sex-Based Differences in Cardiometabolic Biomarkers.

Authors:  Jeanney Lew; Monika Sanghavi; Colby R Ayers; Darren K McGuire; Torbjørn Omland; Dorothee Atzler; Maria O Gore; Ian Neeland; Jarett D Berry; Amit Khera; Anand Rohatgi; James A de Lemos
Journal:  Circulation       Date:  2017-02-07       Impact factor: 29.690

5.  Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI.

Authors:  Gert Klug; Agnes Mayr; Johannes Mair; Michael Schocke; Michael Nocker; Thomas Trieb; Werner Jaschke; Otmar Pachinger; Bernhard Metzler
Journal:  Clin Res Cardiol       Date:  2011-01-04       Impact factor: 5.460

Review 6.  Troponin: the biomarker of choice for the detection of cardiac injury.

Authors:  Luciano Babuin; Allan S Jaffe
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

7.  Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.

Authors:  Carl J Pepine; R David Anderson; Barry L Sharaf; Steven E Reis; Karen M Smith; Eileen M Handberg; B Delia Johnson; George Sopko; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

8.  A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130.

Authors:  Karen A Gelmon; Karl Belanger; Denis Soulieres; Carolyn Britten; Stephen Chia; Danielle Charpentier; Kim Chi; Jean Powers; Wendy Walsh; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-10       Impact factor: 3.850

Review 9.  Gender Disparities in Presentation, Management, and Outcomes of Acute Myocardial Infarction.

Authors:  Matthew Liakos; Puja B Parikh
Journal:  Curr Cardiol Rep       Date:  2018-06-16       Impact factor: 2.931

10.  Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.

Authors:  Christopher B Arant; Timothy R Wessel; Paul M Ridker; Marian B Olson; Steven E Reis; B Delia Johnson; Barry L Sharaf; Daniel F Pauly; Eileen Handberg; Issam Zineh; George Sopko; Sheryl F Kelsey; C Noel Bairey Merz; Carl J Pepine
Journal:  Clin Cardiol       Date:  2009-05       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.